The researchers, led by Welmoed K. Van Deen, MD, of the UCLA Center for Inflammatory Bowel Diseases in Los Angeles, developed a monitoring index for remote assessment of disease activity. They validated the index, which is based on patient-reported outcomes, in 301 patients with Crohn’s disease and 265 patients with ulcerative colitis.
Here’s what you need to know:
1. The index assessed activity of Crohn’s disease based on liquid stool frequency, abdominal pain, patient well-being and patient-assessed disease control
2. The index assessed activity of ulcerative colitis based on stool frequency, abdominal pain, rectal bleeding and patient-assessed disease control.
3. Using a scoring system, the index successfully detected both clinical disease activity and endoscopic activity for those with Crohn’s disease and ulcerative colitis.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
